Halozyme Therapeutics (HALO) Appoints Interim CFO Amid Growth Plans [Yahoo! Finance]
Halozyme Therapeutics, Inc. (HALO)
Last halozyme therapeutics, inc. earnings: 2/24 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
halozyme.com/investors/default.aspx
Company Research
Source: Yahoo! Finance
Therapeutics, Inc. (NASDAQ:HALO) announced the appointment of David Ramsay as the interim Chief Financial Officer, pending the appointment of a permanent CFO. Halozyme Therapeutics, Inc. (HALO) Appoints Interim CFO Amid Growth Plans Likoper/Shutterstock.com Ramsay takes over as CFO with over 30 years of experience in strategic financial leadership across the biotechnology and life sciences sectors. He also boasts of extensive experience in capital markets, corporate finance, and investor relations. He previously served as the company's CFO from 2003 to 2009 and again from 2013 to 2015. During his tenure, the company evolved from a private company to a billion-dollar entity. Earlier on March 11, Halozyme Therapeutics outlined its growth strategy at The Citizens Life Sciences Conference, projecting $1.7–$1.8 billion in revenue for the year, a 22%–30% increase. CEO Helen Torley emphasized the strength of ENHANZE drug-delivery royalties, expected to reach $1.1–$1.2 billion, alongs
Show less
Read more
Impact Snapshot
Event Time:
HALO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HALO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HALO alerts
High impacting Halozyme Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
HALO
News
- Halozyme Therapeutics Touts $1.8B Revenue Outlook, ENHANZE Royalties and New Hypercon Deals at Conference [Yahoo! Finance]Yahoo! Finance
- Halozyme Names Interim CFO As Investors Weigh Valuation And Recent Weakness [Yahoo! Finance]Yahoo! Finance
- Halozyme Appoints David Ramsay as Interim Chief Financial Officer [Yahoo! Finance]Yahoo! Finance
- Halozyme Appoints David Ramsay as Interim Chief Financial OfficerPR Newswire
- Halozyme Therapeutics, Inc. (HALO) Presents at The Citizens Life Sciences Conference 2026 Transcript [Seeking Alpha]Seeking Alpha
HALO
Earnings
- 2/17/26 - Miss
HALO
Sec Filings
- 3/27/26 - Form SCHEDULE
- 3/23/26 - Form 3
- 3/23/26 - Form ARS
- HALO's page on the SEC website